Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.

ABSTRACT: Growth factor and chemotherapy-based stem cell mobilization strategies are commonly used to treat patients with multiple myeloma. We retrospectively compared 398 patients mobilized between 2017 and 2020 using either cyclophosphamide (4 g/m²) plus granulocyte colony-stimulating factor (G-CSF) or G-CSF alone, with on demand plerixafor (PXF) in both groups. Although total CD34⁺ yield was higher after chemomobilization compared with G-CSF +/- PXF (median, 13.6 × 10⁶/kg versus 4.4 × 10⁶/kg; P < .01), achievement of ≥2 × 10⁶ CD34⁺ cells (95% versus 93.7%; P = .61) and rates of mobilization failure (5% versus 6.3%; P = .61) were similar. Fewer patients required PXF with chemomobilization (12.3% versus 49.5%; P < .01), and apheresis

SUBMITTER: Johnsrud A 

PROVIDER: S-EPMC8378276 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature